Mitsubishi UFJ Financial Group Equities Analysts Decrease Earnings Estimates for Charles River Laboratories Intl. Inc (CRL)

Share on StockTwits

Charles River Laboratories Intl. Inc (NYSE:CRL) – Investment analysts at Mitsubishi UFJ Financial Group decreased their Q2 2019 earnings per share (EPS) estimates for Charles River Laboratories Intl. in a research report issued on Wednesday, February 13th. Mitsubishi UFJ Financial Group analyst J. Twizell now anticipates that the medical research company will post earnings per share of $1.62 for the quarter, down from their prior forecast of $1.63. Mitsubishi UFJ Financial Group also issued estimates for Charles River Laboratories Intl.’s FY2019 earnings at $6.45 EPS and Q1 2020 earnings at $1.53 EPS.

A number of other research analysts have also recently weighed in on the company. Zacks Investment Research upgraded Charles River Laboratories Intl. from a “sell” rating to a “hold” rating and set a $156.00 price target for the company in a research report on Thursday, February 14th. Barclays restated a “hold” rating and issued a $135.00 price target on shares of Charles River Laboratories Intl. in a research report on Thursday, February 14th. SunTrust Banks raised their price target on Charles River Laboratories Intl. to $151.00 and gave the company a “buy” rating in a research report on Thursday, February 14th. Jefferies Financial Group restated a “buy” rating and issued a $162.00 price target on shares of Charles River Laboratories Intl. in a research report on Thursday, February 14th. Finally, ValuEngine cut Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Friday, January 4th. Seven analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Charles River Laboratories Intl. currently has an average rating of “Buy” and an average target price of $140.21.

Shares of CRL stock opened at $140.86 on Monday. Charles River Laboratories Intl. has a fifty-two week low of $101.58 and a fifty-two week high of $141.53. The firm has a market capitalization of $6.77 billion, a PE ratio of 23.36, a PEG ratio of 1.83 and a beta of 0.99. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.61 and a quick ratio of 1.32.

Charles River Laboratories Intl. (NYSE:CRL) last announced its quarterly earnings results on Wednesday, February 13th. The medical research company reported $1.49 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.10. Charles River Laboratories Intl. had a return on equity of 24.09% and a net margin of 9.99%. The business had revenue of $605.53 million during the quarter, compared to analysts’ expectations of $589.86 million. During the same quarter last year, the business posted $1.40 earnings per share. The business’s revenue for the quarter was up 26.5% on a year-over-year basis.

A number of large investors have recently modified their holdings of the business. BlackRock Inc. boosted its stake in Charles River Laboratories Intl. by 0.4% in the 4th quarter. BlackRock Inc. now owns 4,530,012 shares of the medical research company’s stock worth $512,709,000 after buying an additional 18,491 shares during the last quarter. FMR LLC boosted its stake in Charles River Laboratories Intl. by 51.9% in the 3rd quarter. FMR LLC now owns 1,869,469 shares of the medical research company’s stock worth $251,518,000 after buying an additional 638,644 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Charles River Laboratories Intl. by 13.8% in the 3rd quarter. Renaissance Technologies LLC now owns 1,724,800 shares of the medical research company’s stock worth $232,055,000 after buying an additional 209,500 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Charles River Laboratories Intl. by 5.9% in the 3rd quarter. Wells Fargo & Company MN now owns 1,394,064 shares of the medical research company’s stock worth $187,556,000 after buying an additional 77,429 shares during the last quarter. Finally, First Trust Advisors LP boosted its stake in Charles River Laboratories Intl. by 28.0% in the 4th quarter. First Trust Advisors LP now owns 1,099,399 shares of the medical research company’s stock worth $124,430,000 after buying an additional 240,437 shares during the last quarter. 99.47% of the stock is currently owned by hedge funds and other institutional investors.

In related news, Chairman James C. Foster sold 1,977 shares of the stock in a transaction on Monday, December 10th. The stock was sold at an average price of $129.11, for a total transaction of $255,250.47. Following the sale, the chairman now owns 267,676 shares of the company’s stock, valued at $34,559,648.36. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Chairman James C. Foster sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, January 8th. The stock was sold at an average price of $115.00, for a total value of $2,875,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 30,417 shares of company stock worth $3,590,419. Corporate insiders own 2.10% of the company’s stock.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Read More: The risks of owning bonds

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Stock Analysts’ Downgrades for March, 19th
Stock Analysts’ Downgrades for March, 19th
Aceto  Stock Price Down 5.3%
Aceto Stock Price Down 5.3%
Pandacoin Price Tops $0.0001 on Major Exchanges
Pandacoin Price Tops $0.0001 on Major Exchanges
Gainer Reaches 24-Hour Trading Volume of $0.00
Gainer Reaches 24-Hour Trading Volume of $0.00
PoSW Coin 24 Hour Trading Volume Hits $3.00
PoSW Coin 24 Hour Trading Volume Hits $3.00
BitDice  24-Hour Volume Hits $7.00
BitDice 24-Hour Volume Hits $7.00


© 2006-2019 Ticker Report